Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duvelisib and Venetoclax in Relapsed or Refractory Peripheral T-cell Lymphoma
NCT06810778Phase 2Recruiting
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- May 2025
- Primary completion
- Jun 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of duvelisib and venetoclax in peripheral T-cell lymphoma (PTCL), sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoints: Dose Limiting Toxicities at 21 days, Maximum Tolerated Dose at 21 days and 1 more. Started May 2025; status: recruiting.
02
Drugs
duvelisibvenetoclax
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT06810778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06810778.